Schnieders Capital Management LLC Decreases Stake in Novo Nordisk A/S $NVO

Schnieders Capital Management LLC reduced its holdings in Novo Nordisk A/S (NYSE:NVO) by 19.1% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 12,606 shares of the company’s stock after selling 2,980 shares during the period. Schnieders Capital Management LLC’s holdings in Novo Nordisk A/S were worth $870,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of the business. Stephens Inc. AR lifted its stake in shares of Novo Nordisk A/S by 1.8% in the second quarter. Stephens Inc. AR now owns 150,409 shares of the company’s stock worth $11,092,000 after buying an additional 2,721 shares in the last quarter. Beverly Hills Private Wealth LLC lifted its stake in shares of Novo Nordisk A/S by 3.9% in the second quarter. Beverly Hills Private Wealth LLC now owns 44,882 shares of the company’s stock worth $3,098,000 after buying an additional 1,679 shares in the last quarter. Balboa Wealth Partners lifted its stake in shares of Novo Nordisk A/S by 6.1% in the second quarter. Balboa Wealth Partners now owns 11,695 shares of the company’s stock worth $807,000 after buying an additional 677 shares in the last quarter. Burford Brothers Inc. lifted its stake in shares of Novo Nordisk A/S by 7.4% in the second quarter. Burford Brothers Inc. now owns 10,826 shares of the company’s stock worth $747,000 after buying an additional 745 shares in the last quarter. Finally, TrueMark Investments LLC lifted its stake in shares of Novo Nordisk A/S by 219.6% in the second quarter. TrueMark Investments LLC now owns 36,151 shares of the company’s stock worth $2,495,000 after buying an additional 24,839 shares in the last quarter. 11.54% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts have recently weighed in on NVO shares. Hsbc Global Res raised shares of Novo Nordisk A/S from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, October 1st. Sanford C. Bernstein raised shares of Novo Nordisk A/S from a “market perform” rating to an “outperform” rating in a research note on Tuesday, September 9th. Wall Street Zen downgraded shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Saturday, August 2nd. Rothschild Redb raised shares of Novo Nordisk A/S from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, September 16th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Novo Nordisk A/S in a research note on Tuesday, October 14th. Two analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Novo Nordisk A/S has an average rating of “Moderate Buy” and an average target price of $76.00.

Novo Nordisk A/S Price Performance

Novo Nordisk A/S stock opened at $54.41 on Monday. The company’s 50 day simple moving average is $56.24 and its 200-day simple moving average is $62.69. The company has a market capitalization of $242.93 billion, a price-to-earnings ratio of 14.95, a price-to-earnings-growth ratio of 2.50 and a beta of 0.68. Novo Nordisk A/S has a 1 year low of $45.05 and a 1 year high of $118.26. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.56 and a current ratio of 0.78.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings results on Wednesday, August 6th. The company reported $0.97 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.93 by $0.04. The business had revenue of $11.69 billion for the quarter, compared to the consensus estimate of $77.51 billion. Novo Nordisk A/S had a net margin of 35.60% and a return on equity of 78.64%. As a group, equities research analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Cuts Dividend

The business also recently declared a semi-annual dividend, which was paid on Tuesday, August 26th. Stockholders of record on Monday, August 18th were paid a $0.4119 dividend. This represents a dividend yield of 240.0%. The ex-dividend date of this dividend was Monday, August 18th. Novo Nordisk A/S’s payout ratio is 22.53%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.